Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2011, Article ID 829751, 4 pages
http://dx.doi.org/10.1155/2011/829751
Review Article

The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis

1Department of Clinical Immunology, University Hospital Alexandrovska, 1 G. Sofiiski Street, 1431 Sofia, Bulgaria
2Department of Dermatovenereology, Varna Medical University, 55 M. Drinov Street, 9000 Varna, Bulgaria

Received 12 June 2011; Revised 28 August 2011; Accepted 28 August 2011

Academic Editor: Eswar Krishnan

Copyright © 2011 Marta Baleva and Krasimir Nikolov. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Scleroderma is progressive autoimmune disease associated with severe disability. The major underlying pathological process in scleroderma is progressive development of fibrous tissue and obliteration of the microvasculature. Currently, there are no medical products for the treatment of scleroderma that provide both sufficient immunosuppression and low-risk side safety profile with negligible side effects. There are a large number of experimental data showing that intravenous immunoglobulin (IVIG) has multiple clinical and morphological effects. On the other hand, some authors report good effect of intravenous immune globulins in patients with scleroderma. The less frequent side effects of IVIG in doses below or equal to 2 g/kg/month divided in 5 consecutive days make IVIG a promising treatment of choice in scleroderma.